SalioGen Therapeutics’ Post

View organization page for SalioGen Therapeutics, graphic

3,724 followers

Today we announced a strategic collaboration with Nanite to develop a non-viral, lung-targeting nanoparticle for our CF genetic medicine. This collaboration represents another important step forward in our R&D efforts to create the first permanent therapy for people with CF, regardless of the mutation. Learn more: https://bit.ly/3R7CEJk

  • No alternative text description for this image

To view or add a comment, sign in

Explore topics